Jefferies Starts Antares Pharma (ATRS) at Buy

Jefferies initiates coverage on Antares Pharma (NASDAQ: ATRS) with a Buy. PT $5.00.

The firm comments, "ATRS is a needle auto-injector innovator transitioning from a device technology partner to an integrated commercial-stage drug company. The primary driver is a self-injected once-weekly form of methotrexate for RA (NDA filed 12/17/12) with better safety and efficacy potential. In the meantime, several already-partnered drugs should fund pre-launch preparations in '13."

For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.

Shares of Antares Pharma closed at $3.82 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• UBS Starts Schrodinger (SDGR) at Neutral
• Axis Capital Limited Assumes Jubilant Foodworks Ltd (JUBI:IN) at Reduce (3)